Novo Nordisk (NVO) stock took a hit this week, after a Super Bowl ad highlighted a growing challenge to the company’s ...

A game-changer for obesity and heart failure? Dr Pandey reveals breakthrough GLP-1 trial results that show reduced cardiovascular risk and better outcomes for HFpEF patients. Don’t miss this!

Health experts say popular weight-loss drugs like Ozempic and Wegovy are safe, but the FDA warns counterfeits are becoming more widespread.

Not content with a $1.2 billion licensing deal for Biohaven ... After its first phase 3 trial of obesity hope CagriSema left investors dissatisfied, Novo Nordisk has a plan to get the programme ...

1 Despite lacking a clear-cut strategy, many companies recognise the potential of GenAI, though 90% of pilots may not reach production. 2 This is where the right partner can add significant value ...